Neurocysticercosis
📧 Sign up to get email alerts when something new happens for Neurocysticercosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Natural History of Treated Neurocysticercosis and Long-Term Outcomes
This clinical trial update outlines the natural history of treated neurocysticercosis and investigates long-term outcomes in affected indivi…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: The Impact of Medical TV Drama in Improving Literacy on Neurocysticercosis [NA]
A planned clinical trial in Ibadan, Nigeria will evaluate whether medical TV drama can improve health literacy about neurocysticercosis and …
-
CLINICAL_TRIALS trial_result · 2025-04-01Clinical Trial Update: Treatment of Peri-calcification Edema in Neurocysticercosis (NCC) [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial investigating treatment of peri-calcification edema in neurocysticercosis has been terminated. The document…
-
FDA approval · 2024-09-04FDA Approved: ALBENDAZOLE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approves Alembic Pharmaceuticals' original application for albendazole, adding a generic version to the market.
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis [Phase 4]
A Phase 4 trial is planned to assess combining praziquantel with albendazole versus albendazole alone for active parenchymal neurocysticerco…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-12-19FDA Approved: BILTRICIDE — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Biltricide (praziquantel) to update the label with expanded indications for treating helminth in…
-
CLINICAL_TRIALS trial_result · 2022-11-16Clinical Trial Update: Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) [Phase 3]
Phase 3 trial update for subarachnoid neurocysticercosis (SANTO) has been TERMINATED.
-
FDA approval · 2021-01-26FDA Approved: ALBENDAZOLE — Original Application (Dr.Reddys Laboratories Inc)
FDA has approved Dr. Reddy's Laboratories Inc for albendazole under an Original Application, confirming the generic's authorization for list…
-
FDA approval · 2021-01-22FDA Approved: ALBENDAZOLE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original application for albendazole from Novadoz Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2019-11-26Clinical Trial Update: Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole [Phase 1]
Phase I trial evaluating safety and pharmacokinetics of oxfendazole for neurocysticercosis has completed with results posted.
-
FDA approval · 2019-05-14FDA Approved: ALBENDAZOLE — Original Application (Edenbridge Pharmaceuticals LLC.)
FDA approved Edenbridge Pharmaceuticals' generic Albendazole as an Original Application under ANDA211117, making a generic version of albend…
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB [Phase 1]
Phase 1 clinical trial evaluating PET imaging of peripheral benzodiazepine receptors in neurocysticercosis using the tracer [F-18]FB; the st…
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: People Presenting With Neurocysticercosis in North America
The NIAID-sponsored clinical trial investigating neurocysticercosis in North America has been terminated.
-
FDA approval · 2017-11-27FDA Approved: PRAZIQUANTEL — Original Application (Endo USA, Inc.)
The FDA approved Endo USA, Inc.'s original application for praziquantel, enabling a generic version of the antihelminthic.
-
CLINICAL_TRIALS trial_result · 2017-02-03Clinical Trial Update: Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients [Phase 3]
Phase 3 clinical trial evaluating whether corticosteroids can reduce seizure frequency in neurocysticercosis has completed.
-
CLINICAL_TRIALS trial_result · 2016-01-01Clinical Trial Update: Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT [Phase 3]
A Phase 3 clinical trial comparing two durations of albendazole therapy in patients with neurocysticercosis (brain involvement with up to 5 …
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis [NA]
A randomized trial evaluated albendazole in patients with epilepsy due to neurocysticercosis; the study has completed.
-
FDA approval · 2014-11-20FDA Approved: BILTRICIDE — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Biltricide (praziquantel) from Bayer HealthCare Pharmaceuticals Inc., authorizing changes to the…
-
CLINICAL_TRIALS trial_result · 2013-08-07Clinical Trial Update: Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ) [Phase 2, Phase 3]
This clinical trial update reports results from a combined treatment with praziquantel and albendazole for neurocysticercosis and related ep…
-
CLINICAL_TRIALS trial_result · 2010-02-08Clinical Trial Update: A Pilot Study of Neurocysticercosis Treatment [Phase 3]
Phase 3 pilot study evaluating treatment for neurocysticercosis has completed.
-
FDA approval · 2009-10-20FDA Approved: ALBENDAZOLE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for Albendazole submitted by Amneal Pharmaceuticals of New York LLC.